Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Intrauterine Misoprostol in Cesarean Delivery: Effect on Postpartum Hemorrhage

11. november 2026 opdateret af: Bagcilar Training and Research Hospital

Evaluation of the Efficacy of Intrauterine Misoprostol Administration on Postpartum Hemorrhage in Cesarean Operations

This prospective, randomized, controlled, two-arm study evaluates whether adding intrauterine (uterine cornual) misoprostol 400 mcg to standard oxytocin reduces postpartum blood loss in term women undergoing elective cesarean delivery. Participants are randomized 1:1 to standard oxytocin alone or standard oxytocin plus misoprostol. The primary outcome is the change in hemoglobin and hematocrit from preoperative values to 6, 24 and 48 hours after surgery.

Studieoversigt

Status

Ikke rekrutterer endnu

Detaljeret beskrivelse

A total of 142 women (71 per group) will be enrolled. The study group receives standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after placental delivery; the control group receives standard oxytocin only. Hemoglobin and hematocrit are measured before surgery and at 6, 24 and 48 hours afterwards, and participants are seen on postoperative day 10 for late complications and adverse events. The surgical team is not masked; participants are not informed of their allocation. An interim safety analysis is planned after 50 participants.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

142

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Istanbul, Tyrkiet (Türkiye)
        • Bagcilar Training and Research Hospital, Department of Obstetrics and Gynecology
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 45 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  • Age 18-45 years
  • Term pregnancy (37 weeks or more)
  • Elective cesarean section planned
  • ASA I-II
  • Written informed consent signed

Exclusion Criteria:

  • History of coagulopathy or active bleeding disorder
  • Anticoagulant use
  • Hemoglobin < 10 g/dL
  • Active thromboembolic disease
  • Severe hepatic failure
  • BMI > 35 kg/m2
  • Type 1 diabetes with diabetic nephropathy
  • Chronic hypertension
  • Gestational hypertension, preeclampsia, eclampsia or HELLP syndrome
  • Placenta previa, placental abruption or placental pathology with high bleeding risk
  • Multiple pregnancy
  • Uterine anomalies
  • Intrauterine fetal death
  • Epilepsy (diagnosis or history)
  • Active malignancy
  • Known hypersensitivity to prostaglandins
  • Refusal or withdrawal of consent
  • Emergency-indicated cesarean sections (including those planned as elective but performed for fetal distress, uterine rupture or other emergency indications)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Misoprostol plus standard oxytocin

Standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after delivery of the placenta during elective cesarean delivery.

Misoprostol 400 mcg (2 x 200 mcg tablets), single dose placed in the uterine cornual region after delivery of the placenta, in addition to standard oxytocin.

Standard oxytocin administered after delivery of the baby according to routine clinical practice (standard of care in both arms).

Aktiv komparator: Standard oxytocin

Standard oxytocin only, according to routine clinical practice, during elective cesarean delivery.

Standard oxytocin administered after delivery of the baby according to routine clinical practice (standard of care in both arms).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in hemoglobin from preoperative value to postoperative 6, 24 and 48 hours
Tidsramme: Preoperative, and 6, 24 and 48 hours after surgery

Hemoglobin (g/dL) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups.

Preoperative, and 6, 24 and 48 hours after surgery
Change in hematocrit from preoperative value to postoperative 6, 24 and 48 hours
Tidsramme: Preoperative, and 6, 24 and 48 hours after surgery

Hematocrit (%) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups.

Preoperative, and 6, 24 and 48 hours after surgery

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Need for blood transfusion
Tidsramme: From surgery until hospital discharge, up to 48 hours

Proportion of participants requiring blood transfusion after surgery.

From surgery until hospital discharge, up to 48 hours
Need for additional uterotonic or hemostatic intervention
Tidsramme: During surgery and until hospital discharge, up to 48 hours

Proportion of participants requiring additional uterotonic agents or other hemostatic interventions.

During surgery and until hospital discharge, up to 48 hours
Late postoperative complications and readmission
Tidsramme: Up to postoperative day 10

Late complications and hospital readmission assessed at the postoperative day 10 visit.

Up to postoperative day 10
Misoprostol-related adverse events
Tidsramme: Up to postoperative day 10

Adverse events potentially related to misoprostol (e.g., fever, shivering, nausea, vomiting, diarrhea) recorded in both groups.

Up to postoperative day 10

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Cem Yener, MD, Associate Professor, Bagcilar Training and Research Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

23. november 2026

Primær færdiggørelse (Anslået)

30. juni 2027

Studieafslutning (Anslået)

30. juni 2027

Datoer for studieregistrering

Først indsendt

11. november 2026

Først indsendt, der opfyldte QC-kriterier

11. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner